Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL685964 | 0.98 | TDP1 (0.41) | TDP1FFAR3 | |
| Bromide SCHEMBL7197738 | 0.98 | TDP1 (0.41) | TDP1 | |
| SCHEMBL106330 | 0.95 | TDP1 (0.43) | TDP1FFAR3 | |
| Bromide SCHEMBL2916644 | 0.83 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL6550644 | 0.80 | — | — | |
| SCHEMBL6727780 | 0.80 | CES2 (0.35) | TDP1FFAR3 | |
| SCHEMBL6550943 | 0.78 | EPHX2 (0.33) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL6548925 | 0.78 | — | — | |
| SCHEMBL6728105 | 0.77 | CES2 (0.36) | FFAR3 | |
| SCHEMBL6731220 | 0.76 | TDP1 (0.38) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638685-B2 | Resolution, sensitivity and smoothness on side surfaces of a transferred pattern; photolithography | NEC CORPORATION (JP) | 2003-10-28 | — | — | US | disclosed |
| US-6602647-B2 | Photo acid generator with high transparency and excellent heat stability in a photoresist for lithography using far ultraviolet light, especially light of ArF excimer consists of a cyclic sulfonium compound with 2-oxo group | NEC CORPORATION (JP) | 2003-08-05 | — | — | US | disclosed |
| US-20020182535-A1 | Photoacid generator containing two kinds of sulfonium salt compound, chemically amplified resist containing the same and pattern transfer method | NEC CORPORATION (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020045122-A1 | Sulfonium salt compound and resist composition and pattern forming method using the same | NEC CORPORATION | 2002-04-18 | — | — | US | disclosed |
| EP-1113334-A1 | Sulfonium salt compound, resist composition comprising the same and pattern forming method using the composition | NEC CORPORATION (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182535-A1 | Photoacid generator containing two kinds of sulfonium salt compound, chemically amplified resist containing the same and pattern transfer method | ASIC1, ASIC3, SULT1A1 | TDP1 2782/4885FFAR3 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.